In meta-analyses of randomized trials of aspirin among patients with prior occlusive vascular disease events (secondary prevention), doses from 75 mg to more than 1500 mg daily provide similar benefits on myocardial infarction, stroke, and cardiovascular death. In acute myocardial infarction and during acute occlusive stroke, a loading dose of 162.5 to 325 mg is necessary to achieve a rapid clinical antithrombotic effect. In primary prevention trials, predominantly among men, aspirin (75 mg daily to 325 mg on alternate days) reduced the risk of a first myocardial infarction. In a large-scale trial in women, aspirin (100 mg on alternate days) reduced risk of a first stroke. In subgroup analyses of women older than age 65, aspirin significantly reduced first myocar-dial infarction and ischemic stroke. Direct comparisons of higher doses may yield additional cardiovascular benefits. At present, daily doses of 75 to 325 mg aspirin are sufficient for long-term treatment and prevention of cardiovascular disease.
Hennekens CH, Godfried SL, Albert CM, Gaziano JM, Buring JE.Adjunctive drug therapy of acute myocardial infarction—evidence from clinical trials. N Engl J Med. 1996;335: 1660-1667.
2.
Pearson T, Blair S, Daniels S, et al.AHA guidelines for primary prevention of cardiovascular diseases and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases. Circulation. 2002;106: 388-391.
3.
Vane JR.Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol.1971;231: 232-235.
Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C.Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353: 2373-2383.
6.
Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high-risk patients. BMJ. 2002;324: 71-86.
7.
Cook NR, Chae CU, Mueller FB, Landis S, Saks AM, Hennekens CH.Mismedication and underutilization of aspirin in the prevention and treatment of cardiovascular disease. Available at MedGenMed1999; http://www.medscape.com/medscape/GeneralMedicine/journal/1999/v01.n11/mgm1122.cook/mgm1122.cook-01.html. Accessed July 21, 2006.
8.
Hunt D, Dientl AF, De Backer G, et al for ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction. Lancet. 1988;2: 349-360.
9.
Collins R, Julian D.British Heart Foundation surveys (1987 and 1989) of United Kingdom treatment policies for acute myocardial infarction. BHJ. 1991;66: 250-255.
10.
Lamas GA, Pfeffer MA, Hamm P, Wertheimer J, Rouleau JL, Braunwald E.Do the results of randomized clinical trials of cardiovascular drugs influence medical practice? The SAVE Investigators. N Engl J Med. 1992;327: 241-247.
11.
Chen ZM, Sandercock P, Pan HC, et al.Indications for early aspirin use in acute ischemic stroke: a combined analysis of 40 000 randomized patients from the Chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups. Stroke. 2000;31: 1240-1249.
12.
Ridker PM, Cook NR, Lee IM, et al.A randomized rrial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352: 1293-1304.
13.
Eidelman RS, Hebert PR, Weisman S, Hennekens CH.An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med. 2003;163: 2006-2010.
14.
Hayden M, Pignone M, Phillips C, Mulrow C.Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;136: 161-172.
15.
Reilly I, Fitzgerald G.Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood. 1987;69: 180-186.
16.
Hennekens CH, Buring JE, Sandercock P, Collins R, Peto R.Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation. 1989;80: 749-756.
17.
Hennekens CH, Dyken ML, Fuster V.Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1997;96: 2751-2753.
18.
García Rodríguez LA, Hernandez-Diaz S, de Abajo FJ, et al.Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol. 2000;52: 563-571.
19.
United Kingdom Transient Ischaemic Attack (UK-TIA) aspirin trial: interim results. UK-TIA Study Group. Br Med J (Clin Res Ed). 1988;296: 316-320.
20.
Topol EJ, Easton D, Harrington RA, et al.Blockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion Trial Investigators. Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation. 2003;108: 399-406.
21.
Peters RJ, Mehta SR, Fox KA, et al; Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Trial Investigators. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation. 2003;108: 1682-1687.
22.
Mustard JF, Packham MA, Kinlough-Rathbone R.Platelets, thrombosis and atherosclerosis. Adv Exp Med Biol. 1978;104: 127-144.
23.
Mustard JF, Packham MA, Kinlough-Rathbone RL.Platelets and thrombosis in the development of atherosclerosis and its complications. Adv Exp Med Biol. 1978;102: 7-30.
24.
Mustard JF, Moore S, Packham MA, Kinlough-Rathbone RL.Platelets, thrombosis and atherosclerosis. Prog Biochem Pharmacol. 1977;13: 312-325.
25.
Mustard JF, Packham MA.The role of blood and platelets in atherosclerosis and the complications of atherosclerosis. Thromb Diath Haemorrh. 1975;33: 444-456.
26.
Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P.Increased proinflamma-tory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation. 1999;100: 793-798.
27.
Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH.Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336: 973-979.
28.
Hennekens CH, Schror K, Weisman S, FitzGerald G.Terms and conditions: semantic complexity and aspirin resistance. Circulation. 2004;110: 1706-1708.
29.
Gum PA, Kottke-Marchant K, Poggio ED, et al.Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001;88: 230-235.
30.
Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ.A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003;41: 961-965.
31.
Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay IE.Aspirin for primary prevention of coronary heart disease, safety and absolute benefit related to coronary risk derived from meta-analysis of randomized trials. Heart. 2001;85: 265-271.
32.
Hennekens CH, Hollar D, Baigent C.Gender Differences in response to aspirin in cardiovascular disease: an hypothesis formulated, but not tested. Nat Clin Prac Cardiovasc Med. 2006,3: 4-6.
33.
United States Preventive Services Task Force. Aspirin for the primary prevention of cardiovascular events—recommendation and rationale. Ann Intern Med. 2002; 136: 157-160.
